Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
heat-killed Faecalibacterium prausnitzii A2-165
- Development stage
- Preclinical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Heat-killed *Faecalibacterium prausnitzii* A2-165 is an inactivated, non-viable form of the A2-165 strain of *F. prausnitzii*, a prominent commensal bacterium in the human gut microbiota. As a postbiotic, it is used in research to investigate the immunomodulatory properties of bacterial structural components independently of active metabolite production (such as butyrate). In studies of inflammatory bowel disease (IBD), heat-killed A2-165 has been shown to be non-inflammatory, specifically failing to induce the expression of dual oxidase 2 (DUOX2) or the production of hydrogen peroxide in colonic epithelial cells, unlike pathobionts such as adherent invasive *Escherichia coli* (AIEC). This makes it a valuable tool for understanding the differential host responses to commensal versus pathogenic microbes in the gut and exploring the therapeutic potential of bacterial ligands in maintaining intestinal homeostasis.
- Other names
- heat-killed F. prausnitzii A2-165inactivated Faecalibacterium prausnitzii A2-165HK-Fp A2-165
02
Targets
IKK complexTLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on heat-killed Faecalibacterium prausnitzii A2-165.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on heat-killed Faecalibacterium prausnitzii A2-165.